DK2421849T3 - Diamidforbindelser med muscarinreceptorantagonist- og beta2-adrenoreceptoragonist-virkning - Google Patents

Diamidforbindelser med muscarinreceptorantagonist- og beta2-adrenoreceptoragonist-virkning

Info

Publication number: DK2421849T3
Authority: DK; Denmark
Prior art keywords: beta2; receptor antagonist; agonist activity; muscarinic receptor; adrenoreceptor agonist
Prior art date: 2009-04-23

Application number

DK10715058.3T

Other languages

English (en)

Inventor

Adam Hughes

Daniel Byun

Yan Chen

Melissa Fleury

John R Jacobsen

Eric L Stangeland

Richard D Wilson

Rose Yen

Original Assignee

Theravance Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-23

Filing date

2010-04-16

Publication date

2013-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2421849(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-16 Application filed by Theravance Inc filed Critical Theravance Inc

2013-07-01 Application granted granted Critical

2013-07-01 Publication of DK2421849T3 publication Critical patent/DK2421849T3/da

Links

229940121786 Beta 2 adrenoreceptor agonist Drugs 0.000 title 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
150000001470 diamides Chemical class 0.000 title 1
230000000694 effects Effects 0.000 title 1
239000003149 muscarinic antagonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK10715058.3T 2009-04-23 2010-04-16 Diamidforbindelser med muscarinreceptorantagonist- og beta2-adrenoreceptoragonist-virkning DK2421849T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17203909P	2009-04-23	2009-04-23
PCT/US2010/031356 WO2010123766A1 (en)	2009-04-23	2010-04-16	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publications (1)

Publication Number	Publication Date
DK2421849T3 true DK2421849T3 (da)	2013-07-01

Family

ID=42272140

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK10715058.3T DK2421849T3 (da)	2009-04-23	2010-04-16	Diamidforbindelser med muscarinreceptorantagonist- og beta2-adrenoreceptoragonist-virkning
DK13151470.5T DK2599778T3 (da)	2009-04-23	2010-04-16	Diamidforbindelser med muskarinreceptorantagonist- og beta-2-adrenergen- receptoragonist-aktivitet
DK17164740.7T DK3210981T3 (da)	2009-04-23	2010-04-16	Diamidforbindelser med muskarinreceptorantagonist- og beta-2-adrenergenreceptoragonist-aktivitet

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK13151470.5T DK2599778T3 (da)	2009-04-23	2010-04-16	Diamidforbindelser med muskarinreceptorantagonist- og beta-2-adrenergen- receptoragonist-aktivitet
DK17164740.7T DK3210981T3 (da)	2009-04-23	2010-04-16	Diamidforbindelser med muskarinreceptorantagonist- og beta-2-adrenergenreceptoragonist-aktivitet

Country Status (32)

Country	Link
US (14)	US8138345B2 (da)
EP (3)	EP2599778B1 (da)
JP (3)	JP5671006B2 (da)
KR (1)	KR101769061B1 (da)
CN (2)	CN103936716B (da)
AR (1)	AR076412A1 (da)
AU (1)	AU2010239522B2 (da)
BR (1)	BRPI1014877B8 (da)
CA (1)	CA2758505C (da)
CL (1)	CL2011002637A1 (da)
CO (1)	CO6440584A2 (da)
CY (2)	CY1119008T1 (da)
DK (3)	DK2421849T3 (da)
ES (3)	ES2417339T3 (da)
HK (1)	HK1165799A1 (da)
HR (3)	HRP20130468T1 (da)
HU (2)	HUE035049T2 (da)
IL (1)	IL215554A (da)
LT (2)	LT3210981T (da)
MX (1)	MX2011011156A (da)
MY (1)	MY158339A (da)
NZ (1)	NZ595850A (da)
PL (3)	PL3210981T3 (da)
PT (3)	PT3210981T (da)
RU (2)	RU2676686C2 (da)
SG (1)	SG175330A1 (da)
SI (3)	SI2421849T1 (da)
SM (1)	SMT201300060B (da)
TR (1)	TR201903556T4 (da)
TW (2)	TWI570115B (da)
WO (1)	WO2010123766A1 (da)
ZA (1)	ZA201107743B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ595850A (en)	2009-04-23	2013-05-31	Theravance Inc	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND Beta2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) *	2010-09-30	2013-01-30	Theravance Inc	Sales oxalato cristalinas de un compuesto diamida
RU2606121C2 (ru)	2011-06-10	2017-01-10	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
AU2012266378B2 (en)	2011-06-10	2017-03-02	Chiesi Farmaceutici S.P.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
AU2013354043C1 (en)	2012-12-06	2017-08-31	Chiesi Farmaceutici S.P.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104854105B (zh)	2012-12-06	2017-05-17	奇斯药制品公司	具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
BR112015013628A2 (pt)	2012-12-18	2017-07-11	Almirall Sa	derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CN104030933A (zh) *	2014-05-16	2014-09-10	烟台恒迪克能源科技有限公司	一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh)	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh)	2015-02-12	2020-09-01	義大利商吉斯藥品公司	具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) *	2015-03-27	2020-07-17	四川海思科制药有限公司	一种杂环衍生物及其制备方法和在医药上的用途
WO2016180349A1 (zh) *	2015-05-14	2016-11-17	四川海思科制药有限公司	具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
WO2016180348A1 (zh) *	2015-05-14	2016-11-17	四川海思科制药有限公司	具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
AR104828A1 (es)	2015-06-01	2017-08-16	Chiesi Farm Spa	COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en)	2015-12-03	2017-06-08	Chiesi Farmaceutici S.P.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201891682A1 (ru) *	2016-01-22	2018-12-28	Сычуань Хайско Фармасьютикал Ко., Лтд.	Производное азациклического амида, способ его получения и фармацевтическое применение
WO2018011090A1 (en)	2016-07-13	2018-01-18	Chiesi Farmaceutici S.P.A.	Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ES2836113T3 (es)	2016-12-14	2021-06-24	Beijing Showby Pharmaceutical Co Ltd	Clase de compuestos bifuncionales con estructura de sal de amonio cuaternario
EP3625232B1 (en)	2017-05-19	2021-06-23	Council of Scientific and Industrial Research	Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2020047225A1 (en)	2018-08-30	2020-03-05	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6362371B1 (en)	1998-06-08	2002-03-26	Advanced Medicine, Inc.	β2- adrenergic receptor agonists
MXPA02005596A (es) *	1999-12-07	2004-09-10	Theravance Inc	Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73543C2 (uk)	1999-12-07	2005-08-15	Тераванс, Інк.	Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US6858596B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en)	2000-08-05	2004-07-06	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative
IL154175A0 (en)	2000-08-05	2003-07-31	Glaxo Group Ltd	17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
US6750210B2 (en)	2000-08-05	2004-06-15	Smithkline Beecham Corporation	Formulation containing novel anti-inflammatory androstane derivative
UA77656C2 (en)	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CN1255012C (zh) *	2001-12-04	2006-05-03	东京研发股份有限公司	供电装置
CN101239971B (zh) *	2003-02-14	2011-07-20	施万制药	联苯衍生物
PE20040950A1 (es) *	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
RS50538B (sr)	2004-01-22	2010-05-07	Pfizer Limited	Sulfonamidni derivati namenjeni lečenju bolesti
WO2005080375A1 (en) *	2004-02-13	2005-09-01	Theravance, Inc.	Crystalline form of a biphenyl compound
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
WO2005092861A1 (en)	2004-03-11	2005-10-06	Pfizer Limited	Quinolinone derivatives pharmaceutical compositions containing them and their use
US7307076B2 (en)	2004-05-13	2007-12-11	Boehringer Ingelheim International Gmbh	Beta agonists for the treatment of respiratory diseases
TWI374883B (en) *	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
JP2008510015A (ja) *	2004-08-16	2008-04-03	セラヴァンス，インコーポレーテッド	β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
US7528253B2 (en) *	2004-08-16	2009-05-05	Theravance, Inc.	Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CA2641706C (en)	2006-02-08	2014-12-23	Fuji Oil Company, Limited	Edible products with low content of saturated and trans unsaturated fats
GB0602778D0 (en) *	2006-02-10	2006-03-22	Glaxo Group Ltd	Novel compound
TW200811105A (en) *	2006-04-25	2008-03-01	Theravance Inc	Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) *	2006-04-25	2008-03-01	Theravance Inc	Crystalline forms of a dimethylphenyl compound
WO2008096129A1 (en)	2007-02-07	2008-08-14	Argenta Discovery Ltd	Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
PL2324018T3 (pl)	2008-07-25	2014-02-28	Boehringer Ingelheim Int	Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
NZ595850A (en)	2009-04-23	2013-05-31	Theravance Inc	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND Beta2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

2010
- 2010-04-16 NZ NZ595850A patent/NZ595850A/xx not_active IP Right Cessation
- 2010-04-16 WO PCT/US2010/031356 patent/WO2010123766A1/en active Application Filing
- 2010-04-16 BR BRPI1014877A patent/BRPI1014877B8/pt not_active IP Right Cessation
- 2010-04-16 MX MX2011011156A patent/MX2011011156A/es active IP Right Grant
- 2010-04-16 US US12/761,532 patent/US8138345B2/en not_active Expired - Fee Related
- 2010-04-16 CA CA2758505A patent/CA2758505C/en not_active Expired - Fee Related
- 2010-04-16 LT LTEP17164740.7T patent/LT3210981T/lt unknown
- 2010-04-16 PT PT17164740T patent/PT3210981T/pt unknown
- 2010-04-16 RU RU2015101032A patent/RU2676686C2/ru active
- 2010-04-16 ES ES10715058T patent/ES2417339T3/es active Active
- 2010-04-16 SG SG2011077765A patent/SG175330A1/en unknown
- 2010-04-16 RU RU2011147374/04A patent/RU2543716C2/ru active
- 2010-04-16 CN CN201410175377.0A patent/CN103936716B/zh not_active Expired - Fee Related
- 2010-04-16 PT PT131514705T patent/PT2599778T/pt unknown
- 2010-04-16 DK DK10715058.3T patent/DK2421849T3/da active
- 2010-04-16 HU HUE13151470A patent/HUE035049T2/en unknown
- 2010-04-16 JP JP2012507275A patent/JP5671006B2/ja not_active Expired - Fee Related
- 2010-04-16 SI SI201030228T patent/SI2421849T1/sl unknown
- 2010-04-16 ES ES13151470.5T patent/ES2635358T3/es active Active
- 2010-04-16 DK DK13151470.5T patent/DK2599778T3/da active
- 2010-04-16 DK DK17164740.7T patent/DK3210981T3/da active
- 2010-04-16 AU AU2010239522A patent/AU2010239522B2/en not_active Ceased
- 2010-04-16 PT PT107150583T patent/PT2421849E/pt unknown
- 2010-04-16 SI SI201031866T patent/SI3210981T1/sl unknown
- 2010-04-16 TR TR2019/03556T patent/TR201903556T4/tr unknown
- 2010-04-16 EP EP13151470.5A patent/EP2599778B1/en active Active
- 2010-04-16 LT LTEP13151470.5T patent/LT2599778T/lt unknown
- 2010-04-16 PL PL17164740T patent/PL3210981T3/pl unknown
- 2010-04-16 KR KR1020117027797A patent/KR101769061B1/ko active IP Right Grant
- 2010-04-16 EP EP17164740.7A patent/EP3210981B1/en active Active
- 2010-04-16 PL PL10715058T patent/PL2421849T3/pl unknown
- 2010-04-16 HU HUE17164740A patent/HUE042975T2/hu unknown
- 2010-04-16 SI SI201031498T patent/SI2599778T1/sl unknown
- 2010-04-16 MY MYPI2011004779A patent/MY158339A/en unknown
- 2010-04-16 ES ES17164740T patent/ES2715965T3/es active Active
- 2010-04-16 CN CN201080017581.XA patent/CN102405218B/zh not_active Expired - Fee Related
- 2010-04-16 EP EP10715058A patent/EP2421849B1/en active Active
- 2010-04-16 PL PL13151470T patent/PL2599778T3/pl unknown
- 2010-04-23 TW TW104129981A patent/TWI570115B/zh not_active IP Right Cessation
- 2010-04-23 AR ARP100101379A patent/AR076412A1/es active IP Right Grant
- 2010-04-23 TW TW099112926A patent/TWI513693B/zh not_active IP Right Cessation
2011
- 2011-10-05 IL IL215554A patent/IL215554A/en active IP Right Grant
- 2011-10-19 CO CO11139777A patent/CO6440584A2/es active IP Right Grant
- 2011-10-21 ZA ZA2011/07743A patent/ZA201107743B/en unknown
- 2011-10-21 CL CL2011002637A patent/CL2011002637A1/es unknown
2012
- 2012-02-08 US US13/369,109 patent/US8551978B2/en active Active
- 2012-07-03 HK HK12106476.6A patent/HK1165799A1/xx not_active IP Right Cessation
2013
- 2013-05-27 HR HRP20130468AT patent/HRP20130468T1/hr unknown
- 2013-06-07 SM SM201300060T patent/SMT201300060B/xx unknown
- 2013-08-12 US US13/964,484 patent/US8816088B2/en not_active Expired - Fee Related
2014
- 2014-07-10 US US14/327,853 patent/US9000173B2/en not_active Expired - Fee Related
- 2014-08-15 JP JP2014165381A patent/JP5965440B2/ja not_active Expired - Fee Related
2015
- 2015-03-04 US US14/638,171 patent/US9394275B2/en active Active
- 2015-05-22 JP JP2015104157A patent/JP2015147807A/ja active Pending
2016
- 2016-06-13 US US15/180,165 patent/US9572802B2/en active Active
- 2016-12-15 US US15/379,673 patent/US9682957B2/en active Active
2017
- 2017-04-26 US US15/497,446 patent/US9771350B2/en active Active
- 2017-05-09 CY CY20171100498T patent/CY1119008T1/el unknown
- 2017-06-26 HR HRP20170960TT patent/HRP20170960T1/hr unknown
- 2017-08-18 US US15/680,323 patent/US9975875B2/en active Active
2018
- 2018-04-23 US US15/959,549 patent/US10138220B1/en not_active Expired - Fee Related
- 2018-10-15 US US16/159,829 patent/US10358433B2/en not_active Expired - Fee Related
2019
- 2019-02-28 CY CY20191100250T patent/CY1121601T1/el unknown
- 2019-03-04 HR HRP20190417TT patent/HRP20190417T1/hr unknown
- 2019-06-07 US US16/434,220 patent/US10590107B2/en not_active Expired - Fee Related
2020
- 2020-01-28 US US16/774,024 patent/US10836744B2/en active Active
- 2020-10-08 US US17/065,689 patent/US20210024493A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US9975875B2 (en)	2018-05-22
TWI570115B (zh)	2017-02-11
BRPI1014877A8 (pt)	2018-03-13
MX2011011156A (es)	2011-11-04
US20190047984A1 (en)	2019-02-14
HRP20190417T1 (hr)	2019-04-19
AU2010239522B2 (en)	2015-07-02
PL2599778T3 (pl)	2018-01-31
US10836744B2 (en)	2020-11-17
RU2676686C2 (ru)	2019-01-10
KR20110138292A (ko)	2011-12-26
US20190300504A1 (en)	2019-10-03
CL2011002637A1 (es)	2012-04-27
ES2715965T3 (es)	2019-06-07
CN103936716A (zh)	2014-07-23
SI2599778T1 (sl)	2017-08-31
HK1165799A1 (en)	2012-10-12
HRP20130468T1 (en)	2013-06-30
US20100273755A1 (en)	2010-10-28
US20130137665A1 (en)	2013-05-30
EP3210981B1 (en)	2019-01-02
CN102405218A (zh)	2012-04-04
EP2599778B1 (en)	2017-04-12
CY1121601T1 (el)	2020-05-29
MY158339A (en)	2016-09-30
HUE042975T2 (hu)	2019-07-29
JP2012524783A (ja)	2012-10-18
CO6440584A2 (es)	2012-05-15
ES2635358T3 (es)	2017-10-03
PT3210981T (pt)	2019-04-01
US8816088B2 (en)	2014-08-26
US9572802B2 (en)	2017-02-21
EP2421849A1 (en)	2012-02-29
US10138220B1 (en)	2018-11-27
CN102405218B (zh)	2014-06-04
US20130331364A1 (en)	2013-12-12
US20200165223A1 (en)	2020-05-28
JP5671006B2 (ja)	2015-02-18
US8138345B2 (en)	2012-03-20
RU2015101032A3 (da)	2018-07-30
TW201041866A (en)	2010-12-01
LT3210981T (lt)	2019-04-10
PT2421849E (pt)	2013-05-27
CA2758505A1 (en)	2010-10-28
US10590107B2 (en)	2020-03-17
TR201903556T4 (tr)	2019-04-22
IL215554A (en)	2014-08-31
AU2010239522A1 (en)	2011-11-10
US10358433B2 (en)	2019-07-23
JP2014210816A (ja)	2014-11-13
NZ595850A (en)	2013-05-31
US20140323733A1 (en)	2014-10-30
LT2599778T (lt)	2017-08-25
JP5965440B2 (ja)	2016-08-03
KR101769061B1 (ko)	2017-08-17
ZA201107743B (en)	2012-06-27
ES2417339T3 (es)	2013-08-07
CA2758505C (en)	2017-03-07
PT2599778T (pt)	2017-06-06
BRPI1014877B8 (pt)	2021-05-25
WO2010123766A1 (en)	2010-10-28
RU2011147374A (ru)	2013-05-27
SI2421849T1 (sl)	2013-07-31
BRPI1014877A2 (pt)	2016-04-12
SMT201300060B (it)	2013-07-09
JP2015147807A (ja)	2015-08-20
SI3210981T1 (sl)	2019-05-31
US9394275B2 (en)	2016-07-19
IL215554A0 (en)	2011-12-29
PL2421849T3 (pl)	2013-08-30
US20170096412A1 (en)	2017-04-06
RU2543716C2 (ru)	2015-03-10
US9771350B2 (en)	2017-09-26
US8551978B2 (en)	2013-10-08
PL3210981T3 (pl)	2019-06-28
SG175330A1 (en)	2011-11-28
US20210024493A1 (en)	2021-01-28
BRPI1014877B1 (pt)	2020-11-10
US20150274697A1 (en)	2015-10-01
RU2015101032A (ru)	2015-06-27
US20170226082A1 (en)	2017-08-10
CN103936716B (zh)	2016-09-07
US20170362200A1 (en)	2017-12-21
US9000173B2 (en)	2015-04-07
DK3210981T3 (da)	2019-04-01
DK2599778T3 (da)	2017-06-26
US9682957B2 (en)	2017-06-20
EP2421849B1 (en)	2013-04-03
HRP20170960T1 (hr)	2017-09-22
CY1119008T1 (el)	2018-01-10
TWI513693B (zh)	2015-12-21
AR076412A1 (es)	2011-06-08
TW201546057A (zh)	2015-12-16
HUE035049T2 (en)	2018-05-02
EP2599778A1 (en)	2013-06-05
US20160361304A1 (en)	2016-12-15
EP3210981A1 (en)	2017-08-30

Publication	Publication Date	Title
DK2421849T3 (da)	2013-07-01	Diamidforbindelser med muscarinreceptorantagonist- og beta2-adrenoreceptoragonist-virkning
LTPA2018011I1 (lt)	2018-06-25	Muskarininio receptoriaus antagonisto ir beta-2 adrenoreceptoriaus agonisto deriniai
HRP20180915T1 (hr)	2018-07-27	Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora
DK2250161T3 (da)	2014-01-27	Forbindelser med CRTH2-antagonistaktivitet
ZA201309242B (en)	2015-05-27	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PL2928890T3 (pl)	2018-07-31	Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
DK2252581T3 (da)	2012-07-16	Kappa-selektiv opioidreceptorantagonist
BRPI0908075A2 (pt)	2015-08-25	Antagonísta muscarínicos de pde4-duplos farmacóforos